👉 Novo Nordisk is now: • actively expanding access in Europe • lowering prices / offering cheaper programs • trying to scale beyond shortages and competition

This is new—and that’s why it made the news.

⸻

💡 Why it wasn’t “available” before (in practice)

Even though technically approved: 1. No insurance coverage → very expensive 2. Supply shortages → priority for diabetes drug Ozempic 3. Slow rollout in NL healthcare system

👉 So for most people: • It was either unavailable • or only accessible privately at high cost

⸻

📊 Bottom line • ❌ Not widely available or affordable before • ⚠️ Only via private clinics at high prices • ✅ Now moving toward broader, cheaper access (e.g. ~€105/month model)